HomeCompareDOCRF vs ABBV

DOCRF vs ABBV: Dividend Comparison 2026

DOCRF yields 9756.10% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DOCRF wins by $43230381229833840.00M in total portfolio value
10 years
DOCRF
DOCRF
● Live price
9756.10%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$43230381229833840.00M
Annual income
$42,375,942,331,967,610,000,000.00
Full DOCRF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — DOCRF vs ABBV

📍 DOCRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDOCRFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DOCRF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DOCRF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DOCRF
Annual income on $10K today (after 15% tax)
$829,268.29/yr
After 10yr DRIP, annual income (after tax)
$36,019,550,982,172,465,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, DOCRF beats the other by $36,019,550,982,172,465,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DOCRF + ABBV for your $10,000?

DOCRF: 50%ABBV: 50%
100% ABBV50/50100% DOCRF
Portfolio after 10yr
$21615190614916920.00M
Annual income
$21,187,971,165,983,804,000,000.00/yr
Blended yield
98.02%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

DOCRF
No analyst data
Altman Z
-7.4
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DOCRF buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDOCRFABBV
Forward yield9756.10%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$43230381229833840.00M$102.3K
Annual income after 10y$42,375,942,331,967,610,000,000.00$24,771.77
Total dividends collected$43173501257510792.00M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: DOCRF vs ABBV ($10,000, DRIP)

YearDOCRF PortfolioDOCRF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$986,310$975,609.76$11,550$430.00+$974.8KDOCRF
2$90,985,578$89,930,226.22$13,472$627.96+$90.97MDOCRF
3$7,850,557,226$7,753,202,657.96$15,906$926.08+$7850.54MDOCRF
4$633,609,188,528$625,209,092,296.54$19,071$1,382.55+$633609.17MDOCRF
5$47,836,734,147,594$47,158,772,315,868.44$23,302$2,095.81+$47836734.12MDOCRF
6$3,378,690,702,500,742$3,327,505,396,962,816.50$29,150$3,237.93+$3378690702.47MDOCRF
7$223,260,494,299,726,370$219,645,295,248,050,560.00$37,536$5,121.41+$223260494299.69MDOCRF
8$13,803,319,479,942,732,000$13,564,430,751,042,025,000.00$50,079$8,338.38+$13803319479942.68MDOCRF
9$798,541,026,043,208,800,000$783,771,474,199,670,000,000.00$69,753$14,065.80+$798541026043208.63MDOCRF
10$43,230,381,229,833,840,000,000$42,375,942,331,967,610,000,000.00$102,337$24,771.77+$43230381229833840.00MDOCRF

DOCRF vs ABBV: Complete Analysis 2026

DOCRFStock

CloudMD Software & Services Inc. operates as a healthcare technology company in North America. The company operates through three segments: Clinic Services & Pharmacies, Digital Health Services, and Enterprise Health Solutions. It offers enterprise health solutions, including mental health support, healthcare navigation, rehabilitation and assessments, education, and absence management and occupational health. The company also provides billing and electronic medical records solutions; MyHealthAccess, a patient portal that enables online appointment booking and virtual care visits; and Health and Wellness, a real time intervention and prevention platform, which enables an automated real time inquiry of disparate data sources in various domains, identify indicators, and compute risk scores. In addition, it offers iMD platform for peer-reviewed educational resources; telemedicine services; and VisionPros, an online vision care platform that provides contact lenses to customers. Further, the company operates a network of hybrid medical and rehabilitation clinics; and medical clinics for family practice and patient care on-site, as well as retails prescription drugs, over-the-counter drugs, and other front store items through two pharmacies. Additionally, it provides patient support programs that offers navigation and support for holistic disease management and clinical treatment outcomes; and pharmaceutical logistic services, including drug distribution and patient navigation assistance, as well as real-time universal disease management software. The company was formerly known as Premier Health Group Inc. and changed its name to CloudMD Software & Services Inc. in February 2020. The company was incorporated in 2013 and is headquartered in Vancouver, Canada.

Full DOCRF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this DOCRF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DOCRF vs SCHDDOCRF vs JEPIDOCRF vs ODOCRF vs KODOCRF vs MAINDOCRF vs JNJDOCRF vs MRKDOCRF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.